Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on PFE stock here.

VTV.vn - Pfizer Vietnam, in collaboration with Vietnam Cancer Association and Vietnam Cancer Immunotherapy Association, ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

The breast cancer treatment market is rapidly growing, driven by advances in technology, personalized therapies and early diagnosis efforts.

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary ...

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...

An Arkansas woman credits immunotherapy for remission as a study shows tumor success, but doctors warn funding cuts could threaten future breakthroughs.

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...